Products for Research Use Only

PIK-75

CAT: 0804-HY-107834-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-107834-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PIK-75 is a reversible DNA-PK and p110α-selective inhibitor, which inhibits DNA-PK, p110α and p110γ with IC50s of 2, 5.8 and 76 nM, respectively. PIK-75 inhibits p110α >200-fold more potently than p110β (IC50=1.3 μM) [1][2]. PIK-75 induces apoptosis[3].
CAS Number
372196-67-3
UNSPSC
12352005
Hazard Statement
H302+H312+H332, H315, H319, H335
Target
Apoptosis; DNA-PK; PI3K
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pik-75-1.html
Concentration
10mM
Purity
99.94
Solubility
DMSO : 13 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=CC([N+]([O-])=O)=CC=C1C)(N(C)/N=C/C2=CN=C3C=CC(Br)=CN32)=O
Molecular Formula
C16H14BrN5O4S
Molecular Weight
452.28
Precautions
H302+H312+H332, H315, H319, H335
References & Citations
[1]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125 (4) :733-47.|[2]Chaussade C, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007 Jun 15;404 (3) :449-58.|[3]Duong HQ, et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 2014 Mar;44 (3) :959-69.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PI3KC2α; PI3KC2β; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34
Citation 01
Adv Sci (Weinh) . 2024 Jun 3:e2400023.|Cell Rep. 2025 Feb 5;44 (2) :115246.|Molecules. 2020 Apr 23;25 (8) :1980.|Clin Cancer Res. 2020 Apr 15;26 (8) :2011-2021. |Res Sq. 2023 Apr 6:rs.3.rs-2688694.